Spec. MD. Huseyin Siddik Soybay

An 8-year-old girl from a family with limited health literacy presented with recurrent abdominal pain. Previous evaluations were inconclusive. Dr. Soybay identified Caroli disease through advanced imaging he personally reviewed. He performed successful endoscopic retrograde cholangiopancreatography (ERCP) with stone extraction and established a long-term surveillance plan, educating the family using simple pictorial guides he created.

A 14-year-old competitive swimmer from a coastal village presented with unexplained jaundice and fatigue. Dr. Soybay discovered a rare case of exercise-induced hyperbilirubinemia combined with Gilbert's syndrome. He designed a unique hydration and training modification protocol, allowing the athlete to continue her sport while managing her condition, leading to a national championship qualification six months later.

A 3-year-old refugee child from a conflict zone arrived with severe malnutrition and suspected liver failure. Dr. Soybay identified an unusual parasitic infection (Fasciola hepatica) uncommon in the region, acquired from contaminated wild plants foraged by the family. Through coordinated nutritional support and targeted antiparasitic treatment, the child made a full recovery over eight weeks, with Dr. Soybay also connecting the family with local support services.

A 7-year-old boy, the only child of two research scientists, presented with puzzling cyclical elevations in liver enzymes. Dr. Soybay diagnosed a very rare metabolic disorder, mitochondrial neurogastrointestinal encephalopathy (MNGIE), through advanced genetic testing he advocated for. He initiated a novel treatment plan involving dietary modifications and coenzyme Q10 supplementation, stabilizing the condition and significantly improving the child's quality of life.

A 2-year-old presented with severe pruritus and failure to thrive. Dr. Soybay diagnosed progressive familial intrahepatic cholestasis type 2 (PFIC2). When conventional treatments provided limited relief, he pioneered the use of a novel ileal bile acid transporter (IBAT) inhibitor through a compassionate use program, resulting in dramatic symptom relief and improved growth parameters.